Atossa Therapeutics announces AACR poster presentation on (Z)-endoxifen in McCune-Albright syndrome

Atossa Therapeutics, Inc.

Atossa Therapeutics, Inc.

ATOS

0.00
  • Atossa Therapeutics released a July 21, 2026 update on preclinical (Z)-endoxifen data in McCune-Albright syndrome presented at an AACR rare cancers meeting.
  • The poster outlined a proposed dual mechanism targeting estrogen receptor signaling, PKC-β/AKT pathways to address peripheral precocious puberty linked to the disorder.
  • Atossa flagged the findings as supporting further evaluation of (Z)-endoxifen in the indication, with potential relevance to estrogen-driven cancers.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607210830PR_NEWS_USPR_____SF08684) on July 21, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.